1. Usmani, S, Ahmadi, T, Ng, Y, et al. Analysis of real-world data on overall survival in multiple myeloma patients With ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist 2016; 21: 1355–1361.
Google Scholar | Crossref | Medline2. de Weers, M, Tai, Y-T, van der Veer, MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840–1848.
Google Scholar | Crossref | Medline | ISI3. Overdijk, MB, Jansen, JHM, Nederend, M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor–mediated cross-linking. J Immunol 2016; 197: 807–813.
Google Scholar | Crossref | Medline4. Lonial, S, Weiss, BM, Usmani, SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016; 387: 1551–1560.
Google Scholar | Crossref | Medline | ISI5. Lokhorst, HM, Plesner, T, Laubach, JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015; 373: 1207–1219.
Google Scholar | Crossref | Medline | ISI6. Usmani, SZ, Weiss, BM, Plesner, T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood 2016; 128: 34–44.
Google Scholar | Crossref7. Richardson, PG, San Miguel, JF, Moreau, P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J 2018; 8: 384–394. doi:10.1182/blood-2015-12-687749
Google Scholar | Crossref8. Krejcik, J, Casneuf, T, Nijhof, IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394. doi: 10.1182/blood-2015-12-687749
Google Scholar | Crossref9. Adams, HC, Stevenaert, F, Krejcik, J, et al. High-Parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytom Part A 2019; 95: 279–289.
Google Scholar | Crossref | Medline10. Oostvogels, R, Jak, M, Raymakers, R, et al. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. Br J Haematol 2018; 183: 60–67.
Google Scholar | Crossref | Medline11. Jelínek, T, Maisnar, V, Pour, L, et al. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. Curr Med Res Opin 2018; 34: 775–783.
Google Scholar | Crossref | Medline12. Usmani, SZ, Diels, J, Ito, T, et al. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: an adjusted treatment comparison. Am J Hematol 2017; 92: E146–E152.
Google Scholar | Crossref | Medline13. Attal, M, Richardson, PG, Rajkumar, SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019; 394: 2096–2107.
Google Scholar | Crossref | Medline14. San-Miguel, JF, Hungria, VTM, Yoon, SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014; 15: 1195–1206.
Google Scholar | Crossref | Medline | ISI15. Laubach, JP, Schjesvold, F, Mariz, M, et al. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol 2021; 22: 142–154.
Google Scholar | Crossref | Medline16. Kumar, SK, Lee, JH, Lahuerta, JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149–157.
Google Scholar | Crossref | Medline | ISI17. Pawlyn, C, Morgan, GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer 2017; 17: 543–556.
Google Scholar | Crossref | Medline18. Chim, CS, Kumar, SK, Orlowski, RZ, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 2018; 32: 252–262.
Google Scholar | Crossref | Medline19. Durer, C, Durer, S, Lee, S, et al. Treatment of relapsed multiple myeloma: evidence-based recommendations. Blood Rev 2020; 39: 100616.
Google Scholar | Crossref | Medline20. Ramasamy, K, Gay, F, Weisel, K, et al. Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options. Blood Rev. 2021; 49(February): 100808. doi:10.1016/j.blre.2021.100808
Google Scholar | Crossref | Medline21. Raje, N, Berdeja, J, Lin, Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726–1737.
Google Scholar | Crossref | Medline22. Lonial, S, Lee, HC, Badros, A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020; 21: 207–221.
Google Scholar | Crossref | Medline23. Mateos, MV, Nahi, H, Legiec, W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol 2020; 7: e370–e380. doi:10.1016/S2352-3026(20)30070-3
Google Scholar | Crossref | Medline